Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
28-Oct-2022
IIQ Appendix 4C & Quarterly Activities Report-September 2022
27-Oct-2022
Canadian Patent Granted for BARD1 Technology
27-Oct-2022
Investor Presentation
27-Oct-2022
Notice of Annual General Meeting
14-Oct-2022
Receipt of R&D Tax Incentive Refund
13-Oct-2022
INOVIQ to Develop SubB2M-Based Test on Nicoya SPR Platform
12-Oct-2022
Appendix 4G and Corporate Governance Statement
6-Oct-2022
Appointment/Resignation of CFO and Company Secretary
3-Oct-2022
Notification of cessation of securities - IIQ
3-Oct-2022
Notice required under listing rule 3.13.1
Previous
1
2
3
4
5
6
Next